SI-BONE (SIBN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.09
- Estimate
- -$0.15
- Surprise
- +39.9%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
SI-BONE (SIBN) reported a narrower loss than forecast — adjusted EPS of -$0.09 against the -$0.15 estimate (a 39.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SIBN Sell at 5.2/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +39.9% surprise compares with a +48.3% four-quarter average. Next scheduled report: 2027-02-22.
What argues against it
- Target reached (-0.5% upside)
- Quality below floor (3.5 < 4.0)
- Momentum score 3.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $23.41
- Stop
- $21.77
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
SIBN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.06B
- P/E (fwd)
- -81.6
- 52-week range
- $11.48–$25.92
- Off 52-week high
- 9.7%
- RSI (14)
- 58
- Volume vs avg
- 0.63×
- Score today
- 5.2/10